Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Phenflutermine

From Wikipedia, the free encyclopedia

Phenflutermine
Clinical data
Other namesPhenflutermin; 3-Trifluoromethyl-N-ethyl-α-methylamphetamine; 3-Trifluoromethyl-N-ethylphentermine; N-Ethyl-α,α-dimethyl-3-trifluoromethylphenethylamine; N-Et-α,α-Me-3-TFMPEA; Fenflutermine
ATC code
  • None
Identifiers
  • N-ethyl-2-methyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
Chemical and physical data
FormulaC13H18F3N
Molar mass245.289 g·mol−1
3D model (JSmol)
  • CCNC(C)(C)CC1=CC(C(F)(F)F)=CC=C1
  • InChI=1S/C13H18F3N/c1-4-17-12(2,3)9-10-6-5-7-11(8-10)13(14,15)16/h5-8,17H,4,9H2,1-3H3
  • Key:DRSIPICEAYYBGT-UHFFFAOYSA-N

Phenflutermine, also known as 3-trifluoromethyl-N-ethyl-α-methylamphetamine or as 3-trifluoromethyl-N-ethylphentermine, is a chemical compound of the phenethylamine, amphetamine, and phentermine families.[1] It is the combined or hybrid derivative of the fenfluramine and phentermine, which were used together in the withdrawn combination anorectic fenfluramine/phentermine (Fen-Phen).[1] The compound was first described in the scientific literature by Daniel Trachsel in his book on phenethylamines in 2013.[1] It is not known to have been synthesized, tested, or otherwise described in the literature.[1] However, both fenfluramine and phentermine are known to act as monoamine releasing agents and to have anorectic effects.[2][3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. Rothman RB, Baumann MH (2000). "Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects". Drug Development Research. 51 (2): 52–65. doi:10.1002/1098-2299(200010)51:2<52::AID-DDR2>3.0.CO;2-H. ISSN 0272-4391.
  3. Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
[edit]